Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Prelude Therapeutics Incorporated has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners. Both cases are being prosecuted within 1 distinct art unit. O DELL, DAVID K is the busiest examiner, handling 1 pending office action.
This concentration in 1 distinct art unit suggests a consistent technical theme for the pending applications. Although the 2 actions are handled by 2 distinct examiners, the shared art unit implies that the examiners likely follow similar guidelines. Practitioners can use this to their advantage by applying successful strategies from one case to the other within the art unit. The 1 pending action per examiner ensures individual attention for each matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18928257 | CDK Inhibitors And Their Use As Pharmaceuticals | O DELL, DAVID K | — |
| 18508666 | BRM Targeting Compounds and Associated Methods of Use | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18928257 | CDK Inhibitors And Their Use As Pharmaceuticals | O DELL, DAVID K | — | §112DP | Non-Final OA | — | Pending | Oct 28, 2024 |
| 18508666 | BRM Targeting Compounds and Associated Methods of Use | LEE, WILLIAM Y | 1623 | §112DP | Non-Final OA | — | Pending | Nov 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial